Methysergide-induced retroperitoneal fibrosis: successful outcome and two new laboratory features.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 9413296.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
A 25-year-old woman sought medical attention because of iliocaval manifestations of retroperitoneal fibrosis while she was taking methysergide. Laboratory studies yielded substantially increased serum procollagen III levels and anticardiolipin antibodies accompanied with anti-beta(2) glycoprotein I, findings not previously described with this disorder. Clinical and laboratory manifestations resolved after cessation of methysergide therapy.
Medical subject headings
- Methysergide
- Retroperitoneal Fibrosis
- Vasoconstrictor Agents